Skip to main content

Advertisement

SpringerLink
Log in

High-Risk Myelodysplastic Syndromes: Chemotherapy, Transplantation, and Beyond

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Allogeneic hematopoietic cell transplantation (HCT) has curative potential for patients with myelodysplastic syndromes (MDS), though with considerable nonrelapse mortality and morbidity. The International Prognostic Scoring System, despite its confines, remains a widely used tool guiding treatment decisions in MDS. The two hypomethylating agents, 5-azacytidine (azacitidine) and 5-aza-2-deoxycytidine (decitabine), are both effective in high-risk MDS, but about 50% of high-risk MDS patients fail to achieve a meaningful response, and these agents offer only a modest survival benefit, with a median response duration of 13 months. The more recent proposed risk models of MDS, as well as modern transplant strategies and expanded alternative donor sources, have helped to increase the number of patients offered curative treatment. As both drug therapy and HCT modalities evolve, treatment decisions are certain to become more complex. Current therapeutic options should view the hypomethylating agents as a way to optimize disease response before (and possibly after) HCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of Importance •• Of Major Importance

  1. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079–2088.

    CAS  PubMed  Google Scholar 

  2. Malcovati L, Porta MG, Pascutto C, et al.: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594–7603.

    Article  PubMed  Google Scholar 

  3. •• Malcovati L, Germing U, Kuendgen A, et al.: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503–3510. This WHO classification-based prognostic scoring system (WPSS) was able to classify patients into five risk groups showing different survivals (median survival, 12 to 103 months) and probabilities of leukemic evolution.

    Article  PubMed  Google Scholar 

  4. Haase D, Germing U, Schanz J, et al.: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385–4395.

    Article  CAS  PubMed  Google Scholar 

  5. Kantarjian H, O’Brien S, Ravandi F, et al.: Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008, 113:1351–1361.

    Article  CAS  PubMed  Google Scholar 

  6. Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002, 20:2429–2440.

    Article  CAS  PubMed  Google Scholar 

  7. Silverman LR, McKenzie DR, Peterson BL, et al.: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895–3903.

    Article  CAS  PubMed  Google Scholar 

  8. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al.: International Vidaza High-Risk MDS Survival Study Group: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(3):223–232.

    Article  CAS  PubMed  Google Scholar 

  9. Kantarjian H, Issa JP, Rosenfeld CS, et al.: Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794–1803.

    Article  CAS  PubMed  Google Scholar 

  10. Kantarjian H, Oki Y, Garcia-Manero G, et al.: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109:52–57.

    Article  CAS  PubMed  Google Scholar 

  11. Kantarjian H, Beran M, Cortes J, et al.: Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006, 106(5):1099–1109.

    Article  CAS  PubMed  Google Scholar 

  12. Kantarjian H, O’Brien S, Cortes J, et al.: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106(5):1090–1098.

    Article  PubMed  Google Scholar 

  13. Oosterveld M, Muus P, Suciu S, et al.: EORTC, EBMT, SAKK, GIMEMA Leukemia Groups and the MD Anderson Cancer Center: Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 2002, 16(9):1615–1621.

    Article  CAS  PubMed  Google Scholar 

  14. Sierra J, Pérez WS, Rozman C, et al.: Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002, 100:1997–2004.

    CAS  PubMed  Google Scholar 

  15. De Witte T, Hermans J, Vossen J, et al.: Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000, 110:620–630.

    Article  PubMed  Google Scholar 

  16. Cutler CS, Lee SJ, Greenberg P, et al.: A decision analysis of allergenic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579–585.

    Article  CAS  PubMed  Google Scholar 

  17. •• Alessandrino EP, Della Porta MG, Bacigalupo A, et al.: WHO classification and WPSS predict post transplant outcome in patients with myelodysplastic syndrome: a study from the GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Blood 2008, 112:895–902. WPSS shows a prognostic significance for both OS and probability of relapse. In patients without excess blasts, multilineage dysplasia and transfusion dependency affected OS and were associated with increased transplant-related mortality.

    Article  CAS  PubMed  Google Scholar 

  18. Guardiola P, Runde V, Bacigalupo A, et al.: Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002, 99:4370–4378.

    Article  CAS  PubMed  Google Scholar 

  19. Flomenberg N, Baxter-Lowe LA, Confer D, et al.: Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood 2004, 104:1923–1930.

    Article  CAS  PubMed  Google Scholar 

  20. Deeg HJ, Storer B, Slattery JT, et al.: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002, 100:1201–1207.

    Article  CAS  PubMed  Google Scholar 

  21. • Majhail NS, Brunstein CG, Tomblyn M, et al.: Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 2008, 14:282–289. The use of RIC and UCB extends the availability of transplant therapy to older patients previously excluded on the basis of age and lack of a compatible donor. On multivariate analysis, graft type had no impact on transplant-related mortality or survival, and the HCT comorbidity index score was the only factor independently predictive for these end points.

    Article  CAS  PubMed  Google Scholar 

  22. Barker JN, Weisdorf DJ, DeFor TE, et al.: Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005, 105:1343–1347.

    Article  CAS  PubMed  Google Scholar 

  23. Warlick ED, Cioc A, Defor T, et al.: Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009, 15:30–38.

    Article  PubMed  Google Scholar 

  24. Scott BL, Storer B, Loken MR, et al.: Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005, 11:65–73.

    Article  PubMed  Google Scholar 

  25. Yakoub-Agha I, de La Salmonière P, Ribaud P, et al.: Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients—report of the French Society of Bone Marrow Transplantation. J Clin Oncol 2000, 18:963–971.

    CAS  PubMed  Google Scholar 

  26. Nakai K, Kanda Y, Fukuhara S, et al.: Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005, 19:396–401.

    Article  CAS  PubMed  Google Scholar 

  27. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, et al.: Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 2008, 14:458–468.

    Article  CAS  PubMed  Google Scholar 

  28. Maris MB, Sandmaier BM, Storer BE, et al.: Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006, 12:454–465.

    Article  CAS  PubMed  Google Scholar 

  29. Field T, Perkins J, Huang Y, et al.: 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009 Jun 22 (Epub ahead of print).

  30. Lübbert M, Bertz H, Rüter B, et al.: Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009 Apr 13 (Epub ahead of print).

  31. De Padua Silva L, de Lima M, Kantarjian H, et al.: Outcome of allogeneic stem cell transplantation after hypomethylating therapy with 2′-deoxy-5 azacytidine for patients with myelodysplastic syndrome [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 1468.

  32. Nevill TJ, Fung HC, Shepherd JD, et al.: Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998, 92:1910–1917.

    CAS  PubMed  Google Scholar 

  33. Onida F, Brand R, van Biezen A, et al.: Impact of cytogenetics on outcome of patients with MDS or secondary AML undergoing allogeneic HSCT from HLA-identical siblings: a retrospective analysis of the EBMT-CLWP [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2653.

  34. Rüter B, Wijermans P, Claus R et al.: Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood 2007, 110:1080–1082.

    Article  PubMed  Google Scholar 

  35. Kolb HJ, Schmid C, Tischer J, et al.: Allogeneic stem cell transplantation for MDS and sAML following reduced intensity conditioning and preemptive donor lymphocyte transfusion [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 324.

  36. Jabbour E, Giralt S, Kantarjian H, et al.: Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899–1905.

    Article  CAS  PubMed  Google Scholar 

  37. Rezvani K, Yong AS, Mielke S, et al.: Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008, 111:236–242.

    Article  CAS  PubMed  Google Scholar 

  38. Anderson JE, Appelbaum FR, Schoch G, et al.: Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996, 14:220–226.

    CAS  PubMed  Google Scholar 

  39. Scott B, Deeg HJ, Storer B, Chauncey T, et al.: Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. Leuk Lymphoma 2004, 45:2409–2417.

    Article  CAS  PubMed  Google Scholar 

  40. Castro-Malaspina H, Harris RE, Gajewski J, et al.: Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002, 99:1943–1951.

    Article  CAS  PubMed  Google Scholar 

  41. Russell JA, Tran HT, Quinlan D, et al.: Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468–476.

    Article  CAS  PubMed  Google Scholar 

  42. de Lima M, Couriel D, Thall PF, et al.: Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857–864.

    Article  PubMed  Google Scholar 

  43. Ho AY, Pagliuca A, Kenyon M, et al.: Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004, 104:1616–1623.

    Article  CAS  PubMed  Google Scholar 

  44. Ma X, Does M, Raza A, et al.: Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007, 109:1536–1542.

    Article  PubMed  Google Scholar 

  45. Wallen H, Gooley TA, Deeg HJ, et al.: Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005, 23:3439–3446.

    Article  PubMed  Google Scholar 

  46. de Lima M, Anagnostopoulos A, Munsell M, et al.: Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865–872.

    Article  PubMed  Google Scholar 

  47. Stuart MJ, Cao TM, Sandmaier BM, et al.: Efficacy of nonmyeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia) [abstract 644]. Blood (ASH Annual Meeting Abstracts) 2003, 102:185a.

    Google Scholar 

  48. Martino R, Iacobelli S, Brand R, et al.: Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836–846.

    Article  CAS  PubMed  Google Scholar 

  49. Scott BL, Sandmaier BM, Storer B, et al.: Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006, 20:128–135.

    Article  CAS  PubMed  Google Scholar 

  50. Lee SJ, Klein J, Haagenson M, et al.: High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576–4583.

    Article  CAS  PubMed  Google Scholar 

  51. Gergis U, Markey K, Greene J, et al.: Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant 2009 Aug 17 (Epub ahead of print).

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, Weill Cornell Medical College, Payson Pavilion, 3rd Floor, 525 East 68th Street, New York, NY, 10065, USA

    Usama Gergis & Usama Wissa

Authors
  1. Usama Gergis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Usama Wissa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Usama Gergis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gergis, U., Wissa, U. High-Risk Myelodysplastic Syndromes: Chemotherapy, Transplantation, and Beyond. Curr Hematol Malig Rep 5, 1–8 (2010). https://doi.org/10.1007/s11899-009-0035-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-009-0035-0

Keywords

Search

Navigation